Thalia Therapeutics Plc

0.57pAs of Sun 8 Nov 2026, 12:00 UTC
LSE:THATHealthcare
Ctry United Kingdom
PE (Fwd) •••
TSR 9Y CAGR (26.39%)
Div yield —
ROE (69.25%)
Biotechnology
Beta (5Y) 0.72
PE TTM —
TSR TTM (4.17%)
Mkt cap £10.21M
ROIC (42.94%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
0.641p
11.55%
(11.25%)
Hold 4|4|11|6|7
4Q25
1Q26
2Q26
3Q26
Earnings per share£
0.01
0.01
0.01
0.01
(4.48%)
5.59%
4.72%
1.10%
Revenue£M
0.972
0.951
0.962
0.939
7.46%
1.51%
5.10%
(0.24%)
Peers (US$13.14M)
Cap (US$)
PE
13.13M
—
Capital
TTM
5Y
10Y
Leveragex
0.895
(0.138)
(0.104)
EBIT/Intx
0.789
0.218
0.222
Own earn%
343.17
1.35
4.59
Sh yield%
24.29
23.60
21.70
Owners
Insiders/Inst%
11.94
45.42
Short interest%
4.79
SBC / revenue%
2.26
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
24
Op margin range%
21–31
$1 testx
—
Incr. ROIC%
8